UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Rheumatoid arthritis drug Rinvoq gets insurance benefit
  • By Kim Eun-young
  • Published 2020.08.07 14:34
  • Updated 2020.08.07 14:34
  • comments 0

AbbVie Korea’s rheumatoid arthritis treatment Rinvoq SR Tab. 15mg (ingredient: upadacitinib) has obtained the national health insurance benefit.

The Health Insurance Review and Assessment Service (HIRA) on Thursday held a meeting of the Drug Reimbursement Evaluation Committee and released the outcomes.

The review committee said Rinvoq was eligible for the insurance benefit. AbbVie Korea won the Ministry of Food and Drug Safety’s approval for Rinvoq as rheumatoid arthritis treatment in June.

As for Novartis Korea’s drug for advanced or metastatic breast cancer Kisqali 200mg, the HIRA said it would allow reimbursement if the company accepts Kisqali’s price as suggested by the HIRA’s drug review committee.

Kisqali is a drug used to treat hormone-receptor-positive (HR+), HER2 negative (HER2-) breast cancer that has spread to other parts of the body after menopause. The treatment suppresses a cyclin-dependent kinase 4 and 6 (CDK4/6) protein, helping the growth and proliferation of cancerous cells.

AbbVie won the FDA nod for Kisqali as the first-line treatment in 2017. It expanded its indication for premenopausal, advanced breast cancer in 2018.

Under the criteria for the national health insurance benefits, the government’s final decision could change if the drug’s detailed reimbursement scope changes. If the approval conditions of the drug change or the government nullifies the license, the final decision is subject to change.

key@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Kim Eun-young
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top